Shazam is this an Artificial Intelligence play . Were going to look. Whats to buy ahead of tax reform debate on whether Airline Stocks could be the big beneficiaries of any tax bill. But we do start with the story thats taken wall street, main street, any street, frankly, by storm, and that is bitcoin. Bitcoin futures popping in their first full day of trading on the cboe Cnbcs Bob Pisani joining us with that story. Bob, everybody is talking about it. It is and its finally happened the good thing is at least trading has happened and relatively orderly we passed 18,000, folks. Bitcoin futures opened 6 00 last night eastern time, 15,000, moved up very, very quickly. Here you see its over 18,000. So its been small, 3,600 contracts, figure the math here. 17,000 p 17,000, 18,000 about 60 million. Thats not a lot but its a start at least heres whats important. Lets go over what exactly a futures contract is, why this is so important first of all, its just agreement to buy or sell a commodity
Beholder. Or in the case of stock market, the buyer beholder. Yet that concept seems to allude so many people who watch the show, when they try to value stocks in the stock market. Today the s p gaining over 0. 6 . In the last two hours, you and i have seen a number of stories about how ridiculous it is thats the tha thats ttha thats tthat tesla, the car 3. 2 million cars last year. Tesla produced 83,000. In the last two years, ford lost 4 billion. Last year tesla lost 4. 3 million. How can teslas stock be worth more than fords . You know some people who say theres no such thing as stupid questions, just stupid answers. Not here. Tesla isnt worth more than ford, its just that there are institutions who are willing to pay more for teslas stock than for fords right now. In the stock markets in the shortterm, all that matters is what someones willing to pay. Lets unpeel the onion on both stocks, first lets compare ford with ford. Four years ago, fords market capitalization stood at 60 bil
Atta Chowdhry, RPh, and Lisa Schrade, PharmD, discuss best practices in coordinating specialty pharmacy services between payers and prescribers to ensure timely access to critical hemophilia treatments.
Russell P. Gollard, MD, FACP, discusses hemophilia patients in their plan, identifying these patients, and treatment with newer monoclonal factor products.